Literature DB >> 24459685

Assessing cerebrospinal fluid abnormalities in neurosyphilis patients without human immunodeficiency virus infection.

Li-Li Liu, Hui-Lin Zhang, Song-Jie Huang, Long Liu, Man-Li Tong, Li-Rong Lin, Yu-Yan Chen, Ya Xi, Xiao-Jing Guo, Ya-Feng Zhang.   

Abstract

Neurosyphilis (NS) caused by Treponema pallidum (T. pallidum) subspecies pallidum, can affect the central nervous system during any stage of the disease. To assess several laboratory parameters for NS diagnosis, we performed a case control study on 42 hospitalized NS patients negative for human immunodeficiency virus (HIV) and 40 syphilis/non-NS patients, excluding NS patients at Xiamen Zhongshan Hospital from June 2010 to June 2011. Multivariate logistic regression model showed that the cerebrospinal fluid white blood cell (CSF-WBC, P = 0.009) levels, the CSF-LDH (P = 0.006) levels, the albumin quotient (P = 0.009) and the IgA index (P = 0.042) were independently associated with high risk of NS. The receiver operator characteristic (ROC) curve analysis revealed that the optimal cut-offs were 10 × 106 cells/L for the CSF-WBC concentration, 19.3 U/L for the CSF lactate dehydrogenase (LDH) concentration, 7.08 for the albumin quotient, and 0.14 for the IgA index. Combining the CSF-WBC level, the CSF-LDH level, the albumin quotient and the IgA index increased the NS diagnosis sensitivity to 97.6%. T. pallidum particle agglutination (TPPA) index significantly correlated with the CSF-WBC (r = 0.453, P = 0.000), the IgA index (r = 0.446, P = 0.000), the albumin quotient (r = 0.262, P = 0.017), and the CSF-LDH (r = − 0.278, P = 0.012), respectively. In addition, there were correlations between the CSF-WBC and the IgA index (r = 0.329, P = 0.003), and between the CSF-WBC and the albumin quotient (r = 0.306, P = 0.005). Our results indicated that simultaneous testing of CSF-WBC levels, albumin quotient, IgA index and CSF-LDH can help predict the likelihood of NS in HIV-negative patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24459685     DOI: 10.1016/j.intimp.2013.10.008

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  5 in total

1.  Novel predictors of neurosyphilis among HIV-negative syphilis patients with neurological symptoms: an observational study.

Authors:  Yao Xiao; Man-Li Tong; Li-Li Liu; Li-Rong Lin; Mei-Jun Chen; Hui-Lin Zhang; Wei-Hong Zheng; Shu-Lian Li; Hui-Ling Lin; Zhi-Feng Lin; Hui-Qin Xing; Jian-Jun Niu; Tian-Ci Yang
Journal:  BMC Infect Dis       Date:  2017-04-26       Impact factor: 3.090

2.  CXCL13 chemokine as a promising biomarker to diagnose neurosyphilis in HIV-negative patients.

Authors:  Yan-Li Zeng; Yi-Qiang Lin; Ning-Ning Zhang; Chao-Ning Zou; Hui-Lin Zhang; Feng Peng; Zhao-Ji Liu; Wei-Hong Zheng; Jiang-Hua Yan; Li-Li Liu
Journal:  Springerplus       Date:  2016-06-16

3.  Serological Response Predicts Normalization of Cerebrospinal Fluid Abnormalities at Six Months after Treatment in HIV-Negative Neurosyphilis Patients.

Authors:  Yao Xiao; Man-Li Tong; Li-Rong Lin; Li-Li Liu; Kun Gao; Mei-Jun Chen; Hui-Lin Zhang; Wei-Hong Zheng; Shu-Lian Li; Hui-Ling Lin; Zhi-Feng Lin; Tian-Ci Yang; Jian-Jun Niu
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

4.  LncRNA Expression in CD4+ T Cells in Neurosyphilis Patients.

Authors:  Li-Li Liu; Shao-Gang Zhu; Xiao-Yong Jiang; Jun Ren; Yong Lin; Ning-Ning Zhang; Man-Li Tong; Hui-Lin Zhang; Wei-Hong Zheng; Hua-Jun Fu; Hai-Juan Luo; Li-Rong Lin; Jiang-Hua Yan; Tian-Ci Yang
Journal:  Front Cell Infect Microbiol       Date:  2017-11-08       Impact factor: 5.293

5.  Clinical prediction and diagnosis of neurosyphilis in HIV-negative patients: a case-control study.

Authors:  Yong Lu; Wujian Ke; Ligang Yang; Zhenyu Wang; Ping Lv; Jing Gu; Chun Hao; Jinghua Li; Yumao Cai; Mei Gu; Hongfang Liu; Wenjing Chen; Xiaohui Zhang; Liuyuan Wang; Yahui Liu; Bin Yang; Huachun Zou; Heping Zheng
Journal:  BMC Infect Dis       Date:  2019-12-02       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.